NCT01116648View on ClinicalTrials.gov

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

April 14, 2010

Primary Completion Date

October 31, 2018

Study Completion Date

February 13, 2026

Conditions
Fallopian Tube CarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Serous AdenocarcinomaOvarian Serous Surface Papillary AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaTriple-Negative Breast Carcinoma
Interventions
PROCEDURE

Biopsy Procedure

Undergo optional tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cediranib Maleate

Given PO

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Olaparib

Given PO

Trial Locations (14)

20850

National Cancer Institute, Rockville

20892

National Institutes of Health Clinical Center, Bethesda

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

46804

Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard, Fort Wayne

46845

Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

60201

NorthShore University HealthSystem-Evanston Hospital, Evanston

60637

University of Chicago Comprehensive Cancer Center, Chicago

90048

Cedars Sinai Medical Center, Los Angeles

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

02129

Massachusetts General Hospital, Charlestown

02462

Newton-Wellesley Hospital, Newton

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH